+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07322913

Post-Market Follow-Up Registry to Assess Safety and Performance of Intervascular Vascular Grafts and Patches in Artery Bypass, Repair, or Replacement

Led by Intervascular · Updated on 2026-09-11

1200

Participants Needed

5

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the long-term safety and performance of Intervascular Vascular Grafts and Patches, including Intergard Standard, Hemashield, Intergard Silver, and Intergard Synergy. These devices are used for bypass, repair, or replacement of aortic, peripheral, or carotid arteries. The study aims to better understand the expected lifetime of these devices and assess the usefulness of their antimicrobial coatings. Participants have undergone surgical procedures using one of these vascular grafts or patches. The devices differ by coating type, including collagen and antimicrobial coatings with agents like silver acetate and triclosan designed to reduce bleeding and inhibit microbial colonization. The registry collects data over an anticipated average of 5 years from the time of their procedure. Participants provide available medical records for data collection, with a minimum of 3 years of follow-up data required. Researchers monitor outcomes such as device patency, freedom from occlusion or reintervention, incidence of major adverse events or limb events, and infection rates. The study assesses device technical success and complications over long-term use, with data gathered through routine clinical care for up to five years post-procedure.

CONDITIONS

Brief Title

Intervascular Post-Market Clinical Follow-Up (PMCF) Registry

Research Team

S

Senior Manager, Clinical Affairs

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here